Maksim Labkouski
Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer Viking Therapeutics (NASDAQ:VKTX) in the list.
In addition to VKTX, Biegler